{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:39:51Z","timestamp":1785886791145,"version":"3.56.0"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the additional treatment value of intravenous immunoglobulin injections for treating interstitial lung disease (ILD) caused by rheumatoid arthritis (RA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This pilot study included patients with RA\u2010ILD. The RA\u2010ILD patients were grouped by treatment agents: traditional agents (disease\u2010modifying antirheumatic drugs, [D]MARDs] and glucocorticoids) and traditional agents plus immunoglobulin. A propensity matching score (PSM) was performed to balance the bias of baseline characteristics. The treatment efficacy and safety indicators were analyzed and compared between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 134 patients were included in this study. After PSM, 80 patients were finally included, with 40 in each group. The immunoglobulin group consisted of 12 men and 28 women with a mean age of 51.5\u2009\u00b1\u20098.4\u2009years (22\u201375\u2009years). The control group included 13 men and 27 women, with a mean age of 50.6\u2009\u00b1\u20098.2\u2009years (25\u201374\u2009years). The chronic obstructive pulmonary disease assessment test score in the immunoglobulin group was statistically lower after treatment than in the control group (19.1\u2009\u00b1\u20093.3 vs. 17.7\u2009\u00b1\u20093.4, <jats:italic>p<\/jats:italic>\u2009=\u2009.03). The 6\u2010min walking distance (364.4\u2009\u00b1\u200954.3 vs. 332.3\u2009\u00b1\u200955.1, <jats:italic>p<\/jats:italic>\u2009=\u2009.04) and forced vital capacity (78.8\u2009\u00b1\u200912.6 vs. 66.6\u2009\u00b1\u200911.2, <jats:italic>p<\/jats:italic>\u2009=\u2009.05) were statistically higher in the immunoglobulin group. The high\u2010resolution computed tomography score and erythrocyte sedimentation rate were both statistically lower in the immunoglobulin group (both <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05). The adverse event rate did not differ between the two groups (<jats:italic>p<\/jats:italic>\u2009=\u2009.61).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The additional use of immunoglobulin intravenous injection is effective for the treatment of RA\u2010ILD with no additional adverse effects.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.14808","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T04:39:20Z","timestamp":1690605560000},"page":"1745-1750","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The additional treatment value of immunoglobulin for the treatment of rheumatoid arthritis complicated with interstitial lung disease: A propensity score\u2010matched pilot study"],"prefix":"10.1111","volume":"26","author":[{"given":"Xiaoxia","family":"Shen","sequence":"first","affiliation":[{"name":"Department of respiratory disease, 72nd Group Army Hospital Huzhou University  Huzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2917-4146","authenticated-orcid":false,"given":"Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of respiratory disease, 72nd Group Army Hospital Huzhou University  Huzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-022-04492-3"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21986"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3097"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102245"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101133"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201004-0622OC"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211138"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171315"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38322"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.15b25.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152004"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040874"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05227-9"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200616"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16500"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2022.05.004"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1509ST"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200403-417OC"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061367"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000081"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7100356"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01086-2"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.04022.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0021-2020"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.14808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T08:48:00Z","timestamp":1693817280000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.14808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/1756-185X.14808"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.14808","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]},"assertion":[{"value":"2022-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}